1. |
Forlino A, Cabral WA, Barnes AM, et al. New perspectives on osteogenesis imperfecta[J]. Nat Rev Endocrinol, 2011, 7(9): 540-557.
|
2. |
van Dijk FS, Cobben JM, Maugeri A, et al. Osteogenesis imperfecta: clinical and genetic heterogeneity[J]. Ned Tijdschr Geneesk, 2012, 156(21): A4585.
|
3. |
Baldridge D, Lennington J, Weis M, et al. Generalized connective tissue disease in Crtap-/- mouse[J]. PloS one, 2010, 5(5): e10560.
|
4. |
Brodeur AC, Wirth DA, Franklin CL, et al. Type I collagen glomerulopathy: postnatal collagen deposition follows glomerular maturation[J]. Kidney Int, 2007, 71(10): 985-993.
|
5. |
Phillips CL, Pfeiffer BJ, Luger AM, et al. Novel collagen glomerulopathy in a homotrimeric type I collagen mouse (oim) [J]. Kidney Int, 2002, 62(2): 383-391.
|
6. |
Roberts-Pilgrim AM, Makareeva E, Myles MH, et al. Deficient degradation of homotrimeric type I collagen, alpha1(I)3 glomerulopathy in oim mice[J]. Mol Genet Metab, 2011, 104(3): 373-382.
|
7. |
Basal S, Ozgok Y, Tahmaz L, et al. Extraperitoneal laparoscopy-assisted percutaneous nephrolithotomy in a patient with osteogenesis imperfecta[J]. Urol Res, 2011, 39(1): 73-76.
|
8. |
Chines A, Boniface A, McAlister W, et al. Hypercalciuria in osteogenesis imperfecta: a follow-up study to assess renal effects[J]. Bone, 1995, 16(3): 333-339.
|
9. |
Venugopala D, Babu S, Korath MP, et al. Renal stone disease as extra skeletal manifestation of osteogenesis imperfecta[J]. J Assoc Physicians India, 2000, 48(10): 1027-1028.
|
10. |
Vetter U, Maierhofer B, Muller M, et al. Osteogenesis imperfecta in childhood: cardiac and renal manifestations[J]. Eur J Pediatr, 1989, 149(3): 184-187.
|
11. |
Vetter U, Pontz B, Zauner E, et al. Osteogenesis imperfecta: a clinical study of the first ten years of life[J]. Calcif Tissue Int, 1992, 50(1): 36-41.
|
12. |
Bhadada SK, Santosh R, Bhansali A, et al. Osteogenesis imperfecta[J]. J Assoc Physicians India, 2009, 57: 33-36.
|
13. |
Bradbury LA, Barlow S, Geoghegan F, et al. Risedronate in adults with osteogenesis imperfecta type I: increased bone mineral density and decreased bone turnover, but high fracture rate persists. Osteoporos Int, 2012, 23(1): 285-294.
|
14. |
Brixen KT, Illum NO, Hansen B, et al. Oesteogenesis imperfecta-genetics, diagnosis and medical treatment[J]. Ugeskr Laeger, 2007, 169(1): 30-34.
|
15. |
Lin HY, Lin SP, Chuang CK, et al. Intravenous pamidronate therapy in Taiwanese patients with osteogenesis imperfecta[J]. Pediatr Neonato, 2008, 49(5): 161-165.
|
16. |
Zacharin M, Kanumakala S. Pamidronate treatment of less severe forms of osteogenesis imperfecta in children[J]. J Pediatr Endocrinol Metab, 2004, 17(11): 1511-1517.
|
17. |
Horvatic I, Galesic K. Membranous glomerulonephritis-recent advances in pathogenesis and treatment[J]. Lijec Vjesn, 2012, 134(11-12): 328-339.
|
18. |
Li X, Xu N, Li H, et al. Tacrolimus as rescue therapy for adult-onset refractory minimal change nephrotic syndrome with reversible acute renal failure[J]. Nephrol Dial Transplant, 2013, 28(9): 2306-2312.
|